Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Given that so many of us are confined at home, it may not feel that way, since it is much easier for the days to simply become a blur, but here we are. We can relate, at least to an extent. We have toiled on the mostly tranquil Pharmalot campus for much of the past 13 years, although our short person is now with us round the clock. So like you, there are adjustments. But certain things do not change, such as firing up the coffee kettle. So here we go. Meanwhile, here are some tidbits. As always, stay safe and stay in touch.

Trump administration officials are asking India to lift restrictions to give the U.S. access to pharmaceutical ingredients to produce a range of drugs amid fears of a U.S. shortage of medicines prompted by the coronavirus outbreak, NBC News reports. The two governments are holding discussions aimed at easing new restrictions on pharmaceutical exports from India, which New Delhi introduced to ensure that the country would have medicine needed to handle the pandemic inside its borders.


Rudy Giuliani, President Trump’s personal attorney, is urging the Food and Drug Administration to fast-track clinical trials of an experimental stem cell therapy in Covid-19 patients, prompting fears of political meddling in a scientific process meant to protect patients, STAT reports. In recent days, Giuliani has used his Twitter account and podcast to tout the stem cell treatment being developed by a New Jersey biotech company, Celularity, despite scant evidence to date that its therapy will benefit Covid-19 patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!